



New Data Insights Unveiled at ASN Kidney Week 2023 Point to the Impact of the Tablo® Hemodialysis System on Equitable Kidney Care

November 1, 2023

Studies reinforce the influence of new technology on effective, efficient kidney care

SAN JOSE, Calif.--(BUSINESS WIRE)--Nov. 1, 2023-- [Outset Medical, Inc.](#) (Nasdaq: OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis with its Tablo® Hemodialysis System, today announced significant data findings on how the use of Tablo increases racial diversity among users, enhances patient outcomes in the Medicare fee-for-service population, and notably decreases hospital transfers in rural Alaskan communities.

The five abstracts will be showcased at the [American Society of Nephrology's \(ASN\) Kidney Week 2023](#) in Philadelphia, PA, which runs November 2-5. The annual event gathers more than 10,000 kidney care professionals from across the globe, offering a forum to delve into the latest advancements in nephrology and to collaborate on kidney care innovation.

"The research abstracts we're presenting at ASN Kidney Week are more than data points; they are a testament to Tablo's adaptability, versatility and its profound impact on equitable healthcare," said Michael Aragon, MD, Chief Medical Officer of Outset Medical. "We're shining a spotlight on the concrete solutions that our data has revealed, solutions that transcend barriers in user diversity, Medicare adoption, rural healthcare and more."

Notable Abstracts & Findings:

- **Characteristics of the First 500 Tablo Home Hemodialysis (HHD) Users** – This retrospective analysis showcases a slightly older and more racially diverse demographic, underscoring the importance of achieving equity across all demographic strata for successful home adoption in the U.S.
- **Characteristics of Tablo Home Hemodialysis Users in Medicare Fee-For-Service** – This early look at Tablo HHD patients in the Medicare fee-for-service population reveals a diverse, catheter-dependent patient group, illuminating a path toward a more inclusive future for kidney care.
- **Patient-Reported Outcomes (PRO) among Patients Receiving Home Hemodialysis** – In this prospective study of 57 patients using Tablo for HHD, preliminary results reveal improved self-reported physical health and reduced symptoms of insomnia, underscoring the positive impact of Tablo-enabled home dialysis on patients' well-being.
- **Rural Alaskan Experience Insourcing Innovative Dialysis Technology** – A case study in rural Alaska shows a marked decrease in hospital transfers and exceptional outcomes since the implementation of Tablo, exemplifying its potential to increase patient access and elevate kidney care in underserved areas. Only a single patient was transferred for care since implementation, versus 71 in the prior year.
- **Designing Memorability and Learnability into Dialysis: Extended Training Decay Periods in a Human Factors Evaluation of the Tablo Hemodialysis System** – A human factors evaluation underscores the ease of use and memorability of Tablo for both healthcare providers and patient/care partner pairs, even after extended training decay periods of up to 28 days.

"Outset's latest research underscores a transformative shift in kidney care, one that points toward patient-centered care, and broadened access to home dialysis in underserved and remote areas," said Leslie Trigg, Chair and Chief Executive Officer of Outset. "We're pushing the boundaries of what's possible in kidney care to create a better option for providers and patients."

The studies can be read in their entirety on the clinical evidence page of the [Outset Medical website](#). Attendees are invited to visit the Outset booth (#1117) during the ASN meeting for more information.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA-cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding Outset's beliefs, projections and expectations concerning, among other things, the potential impact of the research results discussed in this press release. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause actual results and other events to

differ materially from those expressed or implied in such statements. These risks and uncertainties include risks described in the Risk Factors section of Outset's public filings with the U.S. Securities and Exchange Commission, including its latest annual and quarterly reports. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Outset disclaims any obligation to update these forward-looking statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231101481362/en/): <https://www.businesswire.com/news/home/20231101481362/en/>

Nicole Shannon
Director, Marketing Communications for Outset Medical
nshannon@outsetmedical.com

Jim Mazzola
Vice President, Investor Relations for Outset Medical
jmazzola@outsetmedical.com

Source: Outset Medical, Inc.